Induced cell toxicity originates dendritic cell death following magnetic hyperthermia treatment

Cell Death and Disease

Volumn 4, Issue 4, 2013, Pages

  Asin L ^a   Goya, G F ^a   Tres, A ^a,b   Ibarra, M R ^a  

^a UNIVERSITY OF ZARAGOZA   (Spain)

^b HOSPITAL CLÍNICO UNIVERSITARIO LOZANO BLESA   (Spain)

Author keywords

Dendritic cell; Magnetic hyperthermia; Magnetic nanoparticles; Toxicity

Indexed keywords

MAGNETIC NANOPARTICLE; CYTOTOXIC AGENT; MAGNETITE NANOPARTICLE; RHODAMINE;

ALTERNATING MAGNETIC FIELD; ARTICLE; CELL CULTURE; CELL DEATH; CELL POPULATION; CONTROLLED STUDY; CULTURE MEDIUM; DENDRITIC CELL; FLOW CYTOMETRY; HYPERTHERMIC THERAPY; IMMUNE RESPONSE; INCUBATION TIME; LYSOSOME; MAGNETIC FIELD; MAGNETIC HYPERTHERMIA; PERIPHERAL BLOOD MONONUCLEAR CELL; PHAGOCYTOSIS; PRIORITY JOURNAL; RADIOFREQUENCY; TRANSMISSION ELECTRON MICROSCOPY; CYTOTOXICITY; IN VITRO STUDY; MAGNETIC HYPERTHERMIA THERAPY; TEMPERATURE; APOPTOSIS; CHEMISTRY; CYTOLOGY; DRUG EFFECT; HUMAN; NEOPLASM;

EQUIDAE;

APOPTOSIS; CELLS, CULTURED; DENDRITIC CELLS; HUMANS; HYPERTHERMIA, INDUCED; MAGNETIC FIELDS; MAGNETITE NANOPARTICLES; NEOPLASMS; RHODAMINES;

EID: 84879720902     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2013.121     Document Type: Article

References (37)

1. Uzgare AR, Isaacs JT. Prostate cancer: Potential targets of anti-proliferative and apoptotic signaling pathways. Int J Biochem Cell Biol 2005; 37: 707-714
2. Scaffidi C, Fulda S, Srinivasan A, Friesen C, Li F, Tomaselli KJ et al. Two CD95 (APO-1/ Fas) signaling pathways. EMBO J 1998; 17: 1675-1687
3. Guseva NV, Taghiyev AF, Rokhlin OW, Cohen MB. Contribution of death receptor and mitochondrial pathways to Fas-mediated apoptosis in the prostatic carcinoma cell line PC3. Prostate 2002; 51: 231-240
4. Abaan OD, Toretsky JA. PTPL1: A large phosphatase with a split personality. Cancer Metastasis Rev 2008; 27: 205-214
5. Bompard G, Puech C, Pré bois C, Vignon F, Freiss G. Protein-Tyrosine phosphatase PTPL1/FAP-1 triggers apoptosis in human breast cancer cells. J Biol Chem 2002; 277: 47861-47869
6. Dromard M, Bompard G, Glondu-Lassis M, Puech C, Chalbos D, Freiss G. The putative tumor suppressor gene PTPN13/PTPL1 induces apoptosis through insulin receptor substrate-1 dephosphorylation. Cancer Res 2007; 67: 6806-6813
7. Miyazaki T, Atarashi Y, Yasumura S, Minatoya I, Ogawa K, Iwamoto M et al. Fasassociated phosphatase-1 promotes Fas-mediated apoptosis in human colon cancer cells: Novel function of FAP-1. J Gastroenterol Hepatol 2006; 21: 84-91
8. Fahey JW, Zalcmann AT, Talalay P. The chemical diversity and distribution of glucosinolates and isothiocyanates among plants. Phytochemistry 2001; 56: 5-51
9. Xiao D, Johnson CS, Trump DL, Singh SV. Proteasome-mediated degradation of cell division cycle 25C and cyclin-dependent kinase 1 in phenethyl isothiocyanate-Induced G2-M-phase cell cycle arrest in PC-3 human prostate cancer cells. Mol Cancer Ther 2004; 3: 567-575
10. Xiao D, Singh SV. Phenethyl isothiocyanate-Induced apoptosis in p53-deficient PC-3 human prostate cancer cell line is mediated by extracellular signal-regulated kinases. Cancer Res 2002; 62: 3615-3619
11. Xiao D, Lew KL, Zeng Y, Xiao H, Marynowski SW, Dhir R et al. Phenethyl isothiocyanateinduced apoptosis in PC-3 human prostate cancer cells is mediated by reactive oxygen species-dependent disruption of the mitochondrial membrane potential. Carcinogenesis 2006; 27: 2223-2234
12. Xiao D, Zeng Y, Choi S, Lew KL, Nelson JB, Singh SV. Caspase-dependent apoptosis induction by phenethyl isothiocyanate, a cruciferous vegetable-derived cancer chemopreventive agent, is mediated by Bak and Bax. Clin Cancer Res 2005; 11: 2670-2679
13. Xu C, Shen G, Chen C, Gé linas C, Kong AN. Suppression of NF-kappaB and NF-kappaBregulated gene expression by sulforaphane and PEITC through IkappaBalpha, IKK pathway in human prostate cancer PC-3 cells. Oncogene 2005; 24: 4486-4495
14. Rokhlin OW, Bishop GA, Hostager BS, Waldschmidt TJ, Sidorenko SP, Pavloff N et al. Fas-mediated apoptosis in human prostatic carcinoma cell lines. Cancer Res 1997; 57: 1758-1768
15. Uslu R, Borsellino N, Frost P, Garban H, Ng C, Mizutani Y et al. Chemosensitization of human prostate carcinoma cell lines to anti-Fas-mediated cytotoxicity and apoptosis. Clin Cancer Res 1997; 3: 963-972
16. Hedlund TE, Duke RC, Schleicher MS, Miller GJ. Fas-mediated apoptosis in seven human prostate cancer cell lines: Correlation with tumor stage. Prostate 1998; 36: 92-101
17. Steinberg SF. Distinctive activation mechanisms and functions for protein kinase C delta. Biochem J 2004; 384: 449-459
18. Liu Y, Belkina NV, Graham C, Shaw S. Independence of protein kinase C-delta activity from activation loop phosphorylation: Structural basis and altered functions in cells. J Biol Chem 2006; 281: 12102-12111
19. Joo JH, Jetten AM. NF-kappaB-dependent transcriptional activation in lung carcinoma cells by farnesol involves p65/RelA(Ser276) phosphorylation via the MEK-MSK1 signaling pathway. J Biol Chem 2008; 283: 16391-16399
20. Fan C, Yang J, Engelhardt JF. Temporal pattern of NFkappaB activation influences apoptotic cell fate in a stimuli-dependent fashion. J Cell Sci 2002; 115: 4843-4853
21. Gill C, Walsh SE, Morrissey C, Fitzpatrick JM, Watson RW. Resveratrol sensitizes androgen independent prostate cancer cells to death-receptor mediated apoptosis through multiple mechanisms. Prostate 2007; 67: 1641-1653
22. Taghiyev AF, Guseva NV, Sturm MT, Rokhlin OW, Cohen MB. Trichostatin A (TSA) sensitizes the human prostatic cancer cell line DU145 to death receptor ligands treatment. Cancer Biol Ther 2005; 4: 382-390
23. Pullar JM, Thomson SJ, King MJ, Turnbull CI. Midwinter RG, Hampton MB. The chemopreventive agent phenethyl isothiocyanate sensitizes cells to Fas-mediated apoptosis. Carcinogenesis 2004; 25: 765-772
24. Zhuang J, Brady HJ. Emerging role of Mcl-1 in actively counteracting BH3-only proteins in apoptosis. Cell Death Differ 2006; 13: 1263-1267
25. Jackson DN, Foster DA. The enigmatic protein kinase C delta: Complex roles in cell proliferation and survival. FASEB J 2004; 18: 627-636
26. Villar J, Arenas MI, MacCarthy CM, Blánquez MJ, Tirado OM, Notario V. PCPH/ENTPD5 expression enhances the invasiveness of human prostate cancer cells by a protein kinase C delta-dependent mechanism. Cancer Res 2007; 67: 10859-10868
27. Kharait S, Dhir R, Lauffenburger D, Wells A. Protein kinase C delta signaling downstream of the EGF receptor mediates migration and invasiveness of prostate cancer cells. Biochem Biophys Res Commun 2006; 343: 848-856
28. Sumitomo M, Asano T, Asakuma J, Asano T, Nanus DM, Hayakawa M. Chemosensitization of androgen-Independent prostate cancer with neutral endopeptidase. Clin Cancer Res 2004; 10: 260-266
29. Sumitomo M, Ohba M, Asakuma J, Asano T, Kuroki T, Asano T et al. Protein kinase C delta amplifies ceramide formation via mitochondrial signaling in prostate cancer cells. J Clin Invest 2002; 109: 827-836
30. Gonzalez-Guerrico AM, Kazanietz MG. Phorbol ester-Induced apoptosis in prostate cancer cells via autocrine activation of the extrinsic apoptotic cascade: A key role for protein kinase C delta. J Biol Chem 2005; 280: 38982-38991
31. Suh J, Rabson AB. NF-kappaB activation in human prostate cancer: Important mediator or epiphenomenoñ J Cell Biochem 2004; 91: 100-117
32. Nakai Y, Irie S, Sato TA. Identification of IkappaBalpha as a substrate of Fas-Associated phosphatase-1. Eur J Biochem 2000; 267: 7170-7175
33. Li L, Ittmann MM, Ayala G, Tsai MJ, Amato RJ, Wheeler TM et al. The emerging role of the PI3-K-Akt pathway in prostate cancer progression. Prostate Cancer Prostatic Dis 2005; 8: 108-118
34. Cornford P, Evans J, Dodson A, Parsons K, Woolfenden A, Neoptolemos J et al. Protein kinase C isoenzyme patterns characteristically modulated in early prostate cancer. Am J Pathol 1999; 154: 137-144
35. Ré villion F, Puech C, Rabenoelina F, Chalbos D, Peyrat JP, Freiss G. Expression of the putative tumor suppressor gene PTPN13/PTPL1 is an independent prognostic marker for overall survival in breast cancer. Int J Cancer 2009; 124: 638-643
36. Lopez-Beltran A, Mikuz G, Luque RJ, Mazzucchelli R, Montironi R. Current practice of Gleason grading of prostate carcinoma. Virchows Arch 2006; 448: 111-118
37. Castilla C, Congregado B, Chinchón D, Torrubia FJ, Japón MA, Sáez C. Bcl-xL is overexpressed in high-grade prostate cancer and promotes survival of LNCaP cells via interaction with pro-Apoptotic Bak. Endocrinology 2006; 147: 4960-4967